Lawyer who forced big tobacco to pay billions is suing big pharma over US opioid crisis

The 1990s settlement with the tobacco industry still funds smoking cessation and prevention programmes to this day

A pharmacist holds the prescription opioid hydrocodone
A pharmacist holds the prescription opioid hydrocodone

A former Mississippi attorney general who played a central role in holding big tobacco accountable for the health consequences of cigarettes two decades ago has his sights set on another major American industry linked by some to suffering and death.

Mike Moore, a Mississippi lawyer who helped coordinate that effort in the 1990s to hold big tobacco accountable for the marketing that misled Americans about the dangers of smoking, says that the pharmaceutical industry misled the public about the dangers of opioid addiction, which has created one of the biggest health crises in modern US history.

Mr Moore’s leadership 20 years ago eventually resulted in a landmark, $246 billion settlement between big tobacco and 50 states that fund smoking cessation and prevention programmes to this day. Mr Moore calls that settlement the “most historic public health achievement in history.”

In an interview with NBC, Mr Moore said that he works on the effort to hold the pharmaceutical industry every day, and that he is employing what he learned in his fight with tobacco to try and hold the pharmaceutical industry responsible for the opioid epidemic.

“I work this seven days a week because I know at the end, maybe I’ll be a little part of saving a lot of lives,” Mr Moore, 66, said.

So far, that effort has led him to recruit 23 state attorneys general to take on the pharmaceutical industry. The overall strategy, just like with the fight against big tobacco, is to file so many lawsuits that the overall financial burden becomes so high that the pharmaceutical industry agrees to negotiate.

Mr Moore’s name only appears officially on filings from his state, but he is known for having traversed the county to speak with local officials and try to convince them to join in the efforts. Mississippi was among the first of 10 states to sue drug companies. Many of the lawsuits name Purdue Pharmaceuticals as a defendant, which is known for its aggressive promotion of the opioid drug Oxycontin, which they marketed to physicians and patients as having very low addiction rates, relying on a single paragraph in a 1980 letter to the editor in the New England Journal of Medicine to say that just 1 per cent of patients treated with narcotics become addicted.

https://www.bloomberg.com/news/features/2017-10-05/the-lawyer-who-beat-big-tobacco-takes-on-the-opioid-industryThat single paragraph was not peer reviewed.

Purdue also championed the idea of "pseudoaddiction", according to Bloomberg, which is the idea that individuals exhibiting signs of addiction — like asking for drugs by name, or seeking prescriptions from multiple physicians — is actually a sign that the patients need more pain killers, not less.

“When you train your workforce — thousands of salespeople — to go out and tell doctors that there's less than a one percent chance of addiction if you take this drug, and you know that there's no study that you've done, and no reliable study that anybody else has ever done that says that, then of course you're telling a lie,” Mr Moore told the news network.

Purdue did not respond to a request for response to these allegations, but told NBC that Mr Moore’s assessment is “deeply flawed”, and that “illegal trafficking and abuse of heroin and illicit fentanyl” is the real cause of America’s opioid epidemic.

The opioid epidemic is costing the United States tens of billions of dollars a year, and about a quarter of the costs are shouldered by tax payers through the costs associated with health care, criminal justice, and treatment. The epidemic cost the US economy $78.5 billion in 2013, according to the Centers for Disease Control and Prevention.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in